Price ‘Anchoring’? Zolgensma And The Art Of Managing Gene Therapy Sticker Shock
Public statements by Novartis and Avexis suggest Zolgensma could be cost effective at a price up to $5m. Analysts expect $2m. The lower estimate is still stunning, but could it be considered reasonable by comparison?
You may also be interested in...
CEO Nick Leschly talked to Scrip about the European payment strategy for the one-time gene therapy, which will cost €1.575m over five years if treatment is successful.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
A US plant will become the largest of four state-of-the-art sites involved in manufacturing of Novartis unit Avexis' gene therapies headed by Zolgensma, which is widely expected to get the green light from the FDA in May.